Congenital adrenal hyperplasia due to 21-hydroxylase deficiency is caused by biallelic pathogenic variants in CYP21A2 and is inherited in an autosomal recessive manner. Reduced enzyme activity limits cortisol synthesis and, in severe forms, aldosterone, increases ACTH, and favors the excessive production of adrenal androgens.
Congenital adrenal hyperplasia (CAH)
CYP21A2 encodes 21-hydroxylase or cytochrome P450c21, an enzyme of the adrenal cortex. It converts progesterone to 11-deoxycorticosterone and 17-hydroxyprogesterone to 11-deoxycortisol, steps necessary for synthesizing aldosterone and cortisol.
Deficiency reduces cortisol and eliminates its negative feedback, thus increasing ACTH, causing adrenal hyperplasia, and diverting precursors to androgens. There are classic salt-wasting and simple virilizing forms, and a milder nonclassic form. The classic form affects approximately 1 in 10,000-20,000 newborns; the nonclassic form is more frequent, reaching high prevalences in some Ashkenazi Jewish, Mediterranean, Hispanic, and Slavic populations. Clinical expression is variable.
Symptoms
The classic form appears at birth or in the first few weeks. Girls with 46,XX can present with virilization of the external genitalia, while boys usually have normal genitalia. The salt-wasting form causes vomiting, dehydration, weight loss, hyponatremia, hyperkalemia, and risk of adrenal crisis. The simple virilizing form avoids severe salt loss but produces accelerated growth, bone age, premature pubarche, and shorter adult height. The non-classic form debuts later with premature pubarche, acne, hirsutism, menstrual irregularity, or subfertility; some individuals remain asymptomatic.
Disease management
There is no curative treatment. Neonatal screening with 17-hydroxyprogesterone allows for the detection of classic forms before a crisis. Glucocorticoids are administered to replace cortisol and control androgens; the salt-wasting form also requires fludrocortisone and, in infants, sodium. Doses must be adjusted during fever, trauma, or surgery, emergency hydrocortisone must be available, and growth, blood pressure, electrolytes, renin, adrenal steroids, bone age, and fertility must be monitored. The non-classic form is usually treated only if symptomatic. Crinecerfont may be used, where authorized, as an adjunct in the classic form, without replacing glucocorticoids. Gene therapy continues to be investigated.
Genes analyzed
Bibliography
Nimkarn S, Gangishetti PK, Yau M, New MI. 21-Hydroxylase-Deficient Congenital Adrenal Hyperplasia. GeneReviews®. 2002; updated in 2016.
Speiser PW, Arlt W, Auchus RJ, et al. Congenital Adrenal Hyperplasia Due to Steroid 21-Hydroxylase Deficiency: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2018;103(11):4043-4088.
New MI, Abraham M, Gonzalez B, et al. Genotype-phenotype correlation in 1,507 families with congenital adrenal hyperplasia owing to 21-hydroxylase deficiency. Proc Natl Acad Sci U S A. 2013;110(7):2611-2616.
Auchus RJ, Hamidi O, Pivonello R, et al. Phase 3 Trial of Crinecerfont in Adult Congenital Adrenal Hyperplasia. N Engl J Med. 2024;391(6):504-514.
